A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Inclusion Criteria: * Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size≥10%. * Mean hemoglobin level \<100 g/L at screening. * LDH \> 1.5 x Upper Limit of Normal (ULN) at screening. * Vaccination against Neisseria meningitidis infection is required prior to the * start of study treatment. If not received previously, vaccination against * Streptococcus pneumoniae and Haemophilus influenzae infections should be given. Exclusion Criteria: * Known or suspected hereditary or acquired complement deficiency; * Presence or suspicion of a systemic active bacterial, viral, or fungal infection * History of infection with capsular bacteria (e.g., meningococcus, pneumococcus, etc.) * Patients with reticulocytes \<100x10\^9/L; platelets \<30x10\^9/L; neutrophils \<0.5x10\^9/L. * Positive of HIV, HBsAg or HCVAb. * History of recurrent invasive infections caused by encapsulated organisms,e.g. meningococcus or pneumococcus. * Previous splenectomy. * A history of malignancy within 5 years before screening